Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Disease
25%
Clinical Trial
23%
Isoniazid
19%
Infection
18%
Human Immunodeficiency Virus 1
18%
Tuberculosis
17%
Rifapentine
17%
Rilpivirine
16%
Cabotegravir
16%
Human Immunodeficiency Virus Infection
14%
Pharmacokinetics
13%
Efavirenz
12%
Drug Resistant Tuberculosis
12%
RNA Directed DNA Polymerase Inhibitor
11%
Rifampicin
11%
Human Immunodeficiency Virus 1 Infection
10%
Lung Tuberculosis
9%
HIV Associated Dementia
8%
Proteinase Inhibitor
7%
Adverse Event
7%
Nevirapine
7%
Multi-Drug-Resistant Tuberculosis
6%
Atazanavir Plus Ritonavir
6%
Pharmacodynamics
6%
Prevalence
6%
Gamma Interferon
6%
Latent Tuberculosis
5%
Tuberculostatic Agent
5%
Mixed Infection
5%
Zidovudine
5%
Medicine and Dentistry
Human Immunodeficiency Virus
61%
Antiretroviral Therapy
18%
Infection
13%
Tuberculosis
13%
Household
12%
Cabotegravir
12%
Human Immunodeficiency Virus Infection
11%
Disease
11%
Rilpivirine
10%
Clinical Trial
10%
Human Immunodeficiency Virus 1 Infection
9%
Prophylaxis
9%
Human Immunodeficiency Virus 1
9%
Prevalence
7%
Rifampicin
7%
Drug Resistant Tuberculosis
6%
Diagnosis
6%
Pre-Exposure Prophylaxis
6%
Multidrug Resistant Tuberculosis
6%
Low and Middle Income Countries
6%
Hepatitis C Virus
6%
Tenofovir Alafenamide
6%
Cross Sectional Study
5%
Arm
5%
Keyphrases
Human Immunodeficiency Virus Type 1 (HIV-1)
22%
People Living with HIV (PLHIV)
12%
AIDS/HIV
11%
Rifapentine
8%
Antiretroviral Therapy
7%
Long-acting Antiretrovirals
7%
Efavirenz
7%
Tuberculosis
7%
Dementia
6%
Virological Failure
6%
HIV RNA
5%
CD4 Count
5%
Phase II Trial
5%